The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Capsule administered orally per schedule specified in the arm description.
Beijing TiantanHospital, CapitalMedical University
Beijing, Beijing Municipality, China
RECRUITINGXuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGFudan University - Huashan Hospital - Institute of Urology
Shanghai Shi, Shanghai Municipality, China
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to 60 days
Area Under the Plasma Concentration-time Curve From Zero to Last Quantifiable Concentration (AUC0-tlast) of Lu AF28996
Time frame: Days 1, 21 or 31, and 41
Maximum Observed Plasma Concentration (Cmax) of Lu AF28996
Time frame: Days 1, 21 or 31, and 41
Time to Reach Cmax (Tmax) of Lu AF28996
Time frame: Days 1, 21 or 31, and 41
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
RECRUITING